Metachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metachromatic Leukodystrophy - Pipeline Review, H2 2019, provides an overview of the Metachromatic Leukodystrophy (Central Nervous System) pipeline landscape.
Metachromatic leukodystrophy is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. Symptoms include vision problems leading to blindness, personality changes, and motor disturbances such as clumsiness, muscle weakness (hypotonia), rigidity, inability to coordinate movement (ataxia), and/or muscle spasms especially of the neck, spine, arms, and legs. Treatment for metachromatic leukodystrophy is symptomatic and supportive.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metachromatic Leukodystrophy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Metachromatic Leukodystrophy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Metachromatic Leukodystrophy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Metachromatic Leukodystrophy (MLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 1 molecules, respectively.
Metachromatic Leukodystrophy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metachromatic Leukodystrophy - Pipeline Review, H2 2019, provides an overview of the Metachromatic Leukodystrophy (Central Nervous System) pipeline landscape.
Metachromatic leukodystrophy is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. Symptoms include vision problems leading to blindness, personality changes, and motor disturbances such as clumsiness, muscle weakness (hypotonia), rigidity, inability to coordinate movement (ataxia), and/or muscle spasms especially of the neck, spine, arms, and legs. Treatment for metachromatic leukodystrophy is symptomatic and supportive.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metachromatic Leukodystrophy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Metachromatic Leukodystrophy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Metachromatic Leukodystrophy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Metachromatic Leukodystrophy (MLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 1 molecules, respectively.
Metachromatic Leukodystrophy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Metachromatic Leukodystrophy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Metachromatic Leukodystrophy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Metachromatic Leukodystrophy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Metachromatic Leukodystrophy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Metachromatic Leukodystrophy (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Metachromatic Leukodystrophy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Metachromatic Leukodystrophy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Metachromatic Leukodystrophy (MLD) - Overview
Metachromatic Leukodystrophy (MLD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Metachromatic Leukodystrophy (MLD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metachromatic Leukodystrophy (MLD) - Companies Involved in Therapeutics Development
ArmaGen Inc
EnhanX Biopharm Inc
Homology Medicines Inc
Magenta Therapeutics Inc
Orchard Therapeutics Plc
Recursion Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Metachromatic Leukodystrophy (MLD) - Drug Profiles
AGT-183 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUOC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENX-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMI-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGTA-456 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OTL-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Metachromatic Leukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-611 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metachromatic Leukodystrophy (MLD) - Dormant Projects
Metachromatic Leukodystrophy (MLD) - Discontinued Products
Metachromatic Leukodystrophy (MLD) - Product Development Milestones
Featured News & Press Releases
Dec 02, 2019: Orchard Therapeutics announces the filing and validation of marketing authorization application by European Medicines Agency for OTL-200 for the treatment of metachromatic leukodystrophy
Nov 18, 2019: European Medicines Agency grants Orchard Therapeutics accelerated assessment of OTL-200 for patients with Metachromatic Leukodystrophy
Oct 22, 2019: Orchard Therapeutics presents data from OTL-200 in patients with Metachromatic Leukodystrophy using Cryopreservation
Oct 21, 2019: Homology Medicines presents data from investigational MLD gene therapy program HMI-202 at the American Society of Human Genetics (ASHG) 2019 Meeting
Sep 30, 2019: Orchard Therapeutics announces presentation of new clinical data for OTL-200 for Metachromatic Leukodystrophy at upcoming European Society of Gene & Cell Therapy Annual Congress
Sep 04, 2019: Orchard Therapeutics presents an integrated data analysis demonstrating sustained clinical benefit of OTL-200 for the treatment of Metachromatic Leukodystrophy
Sep 04, 2019: Magenta Therapeutics announces FDA regenerative medicine advanced therapy (RMAT) designation granted to MGTA-456 for the treatment of Inherited Metabolic Disorders
Aug 27, 2019: Orchard Therapeutics announces presentation on OTL-200 at Upcoming Society for the Study of Inborn Errors of Metabolism (SSIEM) 2019 Annual Symposium
May 09, 2019: Magenta Therapeutics presents updated phase 2 clinical data on MGTA-456 cell therapy at American Academy of Neurology Annual Meeting
Mar 27, 2019: Orchard Therapeutics presents new registrational data demonstrating sustained clinical benefit of OTL-200 for the treatment of MLD
Mar 11, 2019: Orchard Therapeutics announces acceptance of OTL-200 abstract for MLD at the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT)
Feb 25, 2019: Magenta Therapeutics Presents Clinical and Preclinical Data on MGTA-456 Cell Therapy in Best Abstracts Sessions at Transplant and Cellular Therapy (TCT) Annual Meeting
Dec 02, 2018: Magenta Therapeutics presents new data from phase 2 study of MGTA-456 cell therapy in patients with inherited metabolic disorders
Nov 07, 2018: Homology Medicines presents data on platform's ability to target the central and peripheral nervous system and therapeutic potential in the rare disease Metachromatic Leukodystrophy
Nov 02, 2018: Magenta presents preclinical data on MGTA-456 at ASH annual meeting 2018
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Metachromatic Leukodystrophy (MLD) - Overview
Metachromatic Leukodystrophy (MLD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Metachromatic Leukodystrophy (MLD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metachromatic Leukodystrophy (MLD) - Companies Involved in Therapeutics Development
ArmaGen Inc
EnhanX Biopharm Inc
Homology Medicines Inc
Magenta Therapeutics Inc
Orchard Therapeutics Plc
Recursion Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Metachromatic Leukodystrophy (MLD) - Drug Profiles
AGT-183 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUOC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENX-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMI-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGTA-456 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OTL-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Metachromatic Leukodystrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-611 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metachromatic Leukodystrophy (MLD) - Dormant Projects
Metachromatic Leukodystrophy (MLD) - Discontinued Products
Metachromatic Leukodystrophy (MLD) - Product Development Milestones
Featured News & Press Releases
Dec 02, 2019: Orchard Therapeutics announces the filing and validation of marketing authorization application by European Medicines Agency for OTL-200 for the treatment of metachromatic leukodystrophy
Nov 18, 2019: European Medicines Agency grants Orchard Therapeutics accelerated assessment of OTL-200 for patients with Metachromatic Leukodystrophy
Oct 22, 2019: Orchard Therapeutics presents data from OTL-200 in patients with Metachromatic Leukodystrophy using Cryopreservation
Oct 21, 2019: Homology Medicines presents data from investigational MLD gene therapy program HMI-202 at the American Society of Human Genetics (ASHG) 2019 Meeting
Sep 30, 2019: Orchard Therapeutics announces presentation of new clinical data for OTL-200 for Metachromatic Leukodystrophy at upcoming European Society of Gene & Cell Therapy Annual Congress
Sep 04, 2019: Orchard Therapeutics presents an integrated data analysis demonstrating sustained clinical benefit of OTL-200 for the treatment of Metachromatic Leukodystrophy
Sep 04, 2019: Magenta Therapeutics announces FDA regenerative medicine advanced therapy (RMAT) designation granted to MGTA-456 for the treatment of Inherited Metabolic Disorders
Aug 27, 2019: Orchard Therapeutics announces presentation on OTL-200 at Upcoming Society for the Study of Inborn Errors of Metabolism (SSIEM) 2019 Annual Symposium
May 09, 2019: Magenta Therapeutics presents updated phase 2 clinical data on MGTA-456 cell therapy at American Academy of Neurology Annual Meeting
Mar 27, 2019: Orchard Therapeutics presents new registrational data demonstrating sustained clinical benefit of OTL-200 for the treatment of MLD
Mar 11, 2019: Orchard Therapeutics announces acceptance of OTL-200 abstract for MLD at the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT)
Feb 25, 2019: Magenta Therapeutics Presents Clinical and Preclinical Data on MGTA-456 Cell Therapy in Best Abstracts Sessions at Transplant and Cellular Therapy (TCT) Annual Meeting
Dec 02, 2018: Magenta Therapeutics presents new data from phase 2 study of MGTA-456 cell therapy in patients with inherited metabolic disorders
Nov 07, 2018: Homology Medicines presents data on platform's ability to target the central and peripheral nervous system and therapeutic potential in the rare disease Metachromatic Leukodystrophy
Nov 02, 2018: Magenta presents preclinical data on MGTA-456 at ASH annual meeting 2018
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Metachromatic Leukodystrophy (MLD), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline by ArmaGen Inc, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline by EnhanX Biopharm Inc, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline by Homology Medicines Inc, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline by Magenta Therapeutics Inc, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline by Orchard Therapeutics Plc, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline by Recursion Pharmaceuticals Inc, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Metachromatic Leukodystrophy (MLD) - Dormant Projects, H2 2019
Metachromatic Leukodystrophy (MLD) - Discontinued Products, H2 2019
Number of Products under Development for Metachromatic Leukodystrophy (MLD), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline by ArmaGen Inc, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline by EnhanX Biopharm Inc, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline by Homology Medicines Inc, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline by Magenta Therapeutics Inc, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline by Orchard Therapeutics Plc, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline by Recursion Pharmaceuticals Inc, H2 2019
Metachromatic Leukodystrophy (MLD) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Metachromatic Leukodystrophy (MLD) - Dormant Projects, H2 2019
Metachromatic Leukodystrophy (MLD) - Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development for Metachromatic Leukodystrophy (MLD), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
ArmaGen Inc
EnhanX Biopharm Inc
Homology Medicines Inc
Magenta Therapeutics Inc
Orchard Therapeutics Plc
Recursion Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Number of Products under Development for Metachromatic Leukodystrophy (MLD), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
ArmaGen Inc
EnhanX Biopharm Inc
Homology Medicines Inc
Magenta Therapeutics Inc
Orchard Therapeutics Plc
Recursion Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
